Total antioxidant capacity, hydrogen peroxide, malondialdehyde and total nitric oxide concentrations in patients with severe persistent allergic asthma: Its relation to omalizumab treatment

Clinical Laboratory

Volumn 58, Issue 1-2, 2012, Pages 89-96

  Yalcin, Arzu Didem ^a   Gorczynski, Reginald M ^b   Parlak, Gizem Esra ^c   Kargi, Aysegul ^d   Bisgin, Atil ^c   Sahin, Emel ^c   Kose, Sukran ^e   Gumuslu, Saadet ^c  

^a Antalya Education and Research Hospital   (Turkey)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c AKDENIZ UNIVERSITY   (Turkey)

^d Denizli Education and Training Hospital   (Turkey)

^e Allergology and Clinical Immunology Unit   (Turkey)

Author keywords

Allergic asthma; Antioxidant; Hydrogen peroxide; Malondialdehyde; Nitric oxide; Omalizumab

Indexed keywords

ANTINUCLEAR ANTIBODY; ANTIOXIDANT; CELL MARKER; HYDROGEN PEROXIDE; IMMUNOGLOBULIN E; NITRIC OXIDE; OMALIZUMAB;

ALLERGIC ASTHMA; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; EOSINOPHIL; EOSINOPHIL COUNT; FEMALE; FOLLOW UP; HEALTH STATUS; HOSPITAL; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MALE; OXIDATIVE STRESS; SAMPLE;

ADULT; ANTI-ASTHMATIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; FEMALE; HUMANS; HYDROGEN PEROXIDE; IMMUNOGLOBULIN E; MALE; MALONDIALDEHYDE; NITRIC OXIDE; OXIDATIVE STRESS; RESPIRATORY HYPERSENSITIVITY; SKIN TESTS;

EID: 84857378855     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. GINA (The Global Initiative For Asthma). 2009 p.69.
2. Yalcin AD, Oncel S, Akcan A, Eravsar K, Polat HH, Terzioglu E. Prevalance of allergic asthma, rhinitis and conjunctivitis in over 16 year old individuals in Antalya. Turkiye Klinikleri J Med Sci 2010;30(3):888-94.
3. Bousquet J, Cabrera P, Berkman N, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005;60:302-8. (Pubitemid 40293345)
4. Lotvall J, Akdis C, Bacharier LB, et al. Asthma endotypes: A new approach to classification of disease entities within the asthma syndrome. 2011 AAAAI doi:10.1016/j.jaci.2010.11.037.
5. Kumar, Vinay, Abbas, et al. Robbins and Cotran Pathologic basis of disease (8th ed.). Saunders 2010 p. 688-99.
6. Moore WC, Pascual RM. "Update in asthma 2009". Am J Respir Crit Care Med 2010;181(11):1181-7.
7. Chervinsky P, Casale T, Townley R, et al. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol 2003;91:160-7. (Pubitemid 36999475)
8. Ayres JG, Higgins B, Chilvers ER, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 2004;59:701-8. (Pubitemid 38850344)
9. Yalcin AD, Bisgin A, Çetinkaya R, Gümüslü S, Clinical Efficacy Of Omalizumab In Severe Persistent Asthma And Co-Morbid Conditions. Congress of the European Academy of Allergy and Clinical Immunology. P:946, s:154, 11-15 June.2011 TURKEY DOI: 10.3252/pso.eu.30eaaci.2011.
10. Yalcin AD, Bisgin A, Kargi A, Gorczynski RM. Serum soluble TRAIL levels in patients with severe persistent allergic asthma: its relation to Omalizumab treatment. Med Sci Monitor 2012; Manuscript no: 16729. (accepted 20/9/2011).
11. Casale TB, Condemi J, LaForce C, et al. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA 2001;286:2956-67. (Pubitemid 33140359)
12. Adelroth E, Rak S, Haahtela T, et al. Recombinant humanized mAbE25, an antiIgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2000;106:253-9. (Pubitemid 30644998)
13. Hanf G, Noga O, O'Connor A, Kunkel G. Omalizumab inhibits allergen challenge-induced nasal response. Eur Respir J 2004;23(3):414-8. (Pubitemid 38344378)
14. Kaplan AP, Joseph K, Maykut RJ, Geba GP, Zeldin RK. Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol 2008;122(3):569-73.
15. Rafi A, Do LT, Katz R, Sheinkopf LE, Simons CW, Klaustermeyer W. Effects of omalizumab in patients with food allergy. Allergy Asthma Proc 2010;31(1):76-83.
16. Galera C, Soohun N, Zankar N, Caimmi S, Gallen C, Demoly P. Severe anaphylaxis to bee venom immunotherapy: efficacy of pretreatment and concurrent treatment with omalizumab. J Investig Allergol Clin Immunol 2009;19(3):225-9.
17. Leynadier F, Doudou O, Gaouar H, et al. Effect of omalizumab in health care workers with occupational latex allergy. J Allergy Clin Immunol 2004;113:360-1. (Pubitemid 38210566)
18. Yalcin AD, Cakin O, Polat HH, Terzioglu E. Occupational disease of healthcare workers: Latex allergy. Erciyes Medical Journal 2011:33(2);103-10.
19. Sin AZ. Anti IgE Therapy for Asthma. Turkiye Klinikleri J Int Med Sci 2007;3(23):60-8.
20. Yalcin AD, Gorczynski RM. Anti Ig E therapy, Erciyes Medical Journal 2012, February (in press).
21. Spector SL, Tan RA. Effect of omalizumab on patients with chronic urticaria. Ann Allergy Asthma Immunol 2007;99:190-3. (Pubitemid 47264781)
22. Schulze J, Rose M, Zielen S, Beekeepers anaphylaxis: successful immunotherapy covered by omalizumab J Investig Allergol Clin Immunol 2007;62(8):963-4. (Pubitemid 47037850)
23. Klunker S, Saggar L, Seyfert-Margolis V, Asare A, Casale T, Durham S, Francis J. Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding. Journal of Allergy and Clinical Immunology 2007;120(3):688-95. (Pubitemid 47320761)
24. Clienti S, Morjaria JB, Basile E, Polosa R. Monoclonal antibodies for the treatment of severe asthma. Curr Allergy Asthma Rep 2011 Mar 1. [Epub ahead of print].
25. Hamelmann E. The rationale for treating allergic asthma with anti-IgE. Eur Respir Rev2007;16:61-6. (Pubitemid 350075091)
26. Yanagisava M, Kurihara S, Kurima Y. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-5.
27. Sugiura H, Ichinose M. Oxidative and nitrative stress in bronchial asthma. Antioxid Redox Signal 2008;10:785-97. (Pubitemid 351225897)
28. Riedl MA, Nel AE. Importance of oxidative stress in the pathogenesis and treatment of asthma. Curr Opin Allergy Clin Immunol 2008;8:49-56.
29. Brown DI, Griendling KK. Nox proteins in signal transduction. Free Radic Biol Med 2009;47;1239-53.
30. Terada LS. Specificity in reactive oxidant signaling: think globally, act locally. J Cell Biol 2006;174;615-23.
31. Yalcin AD, Ozcaglar H, Gumuslu S. Investigation of amonium inhalation effects on rat respiratory mucosa by immunohistochemical and electron microscopy and effects of amonium inhalation on antioxidant enzyme activities in rat erythrocytes, (oral presentation - third prize winner in 9th International Otorhinolaryngology and Head Neck Surgery Congress) 8-10 April Ankara, Turkey, S34, 2010.
32. Gumuslu S, Akbas H, Aliciguzel Y, et al. Effects of sulfur dioxide inhalation on antioxidant enzyme activities in rat erythrocytes. Ind Health 1998;36:70-3. (Pubitemid 28087806)
33. Gumuslu S, Sarikcioglu Bilmen S, Sahin E, et al. Influences of different stress models on the antioxidant status and lipid peroxidation in rat erythrocytes. Free Radic Res 2002;36(12):1277-82. (Pubitemid 35469512)
34. Gumral N, Naziroglu M, Ongel K, et al. Antioxidant enzymes and melatonin levels in patients with bronchial asthma and chronic obstructive pulmonary disease during stable and exacerbation periods. Cell Biochem Funct. 2009 Jul;27(5):276-83.
35. Dodig S, Richter D, Zrinski-Topić R. Review: Inflammatory markers in childhood asthma. Clin Chem Lab Med. 2011 Feb 9. [Epub ahead of print].
36. Zhao J, Endoh I, Hsu K, Tedla N, Endoh Y, Geczy CL. S100a8 modulates mast cell function and suppresses eosinophil migration in acute asthma. Antioxid Redox Signal. 2010 Dec 9. [Epub ahead of print].
37. Djukanović R, Wilson SJ, Kraft M, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 2004;170:583-93.
38. Redington AE, Springall DR, Meng QH, et al. Immunoreactive endothelin in bronchial biopsy specimens: increased expression in asthma and modulation by corticosteroid therapy. J Allergy Clin Immunol 1997;100:544-52. (Pubitemid 27441314)
39. Redington AE, Springall DR, Ghatei MA, et al. Endothelin in bronchoalveolar lavage fluid and its relation to airflow obstructtion in asthma. Am J Respir Crit Care Med 1995;151:1034-49.
40. Ehrenreich HR, Anderson CH, Fox P, et al. Endothelins, peptides with potent vasoactive properties are produced by human macrophages. J Exp Med 1990;172:1741-8.
41. Xu J, Zhong NS. The interaction of tumor necrosis factor and endothelin-1 in pathogenic models of asthma. Clin Exp Allergy 1997;27:568-73. (Pubitemid 27241656)
42. Massanari M, Holgate ST, Busse WW, Jimenez P, Kianifard F, Zeldin R. Effect of omalizumab on peripheral blood eosinophilia in allergic asthma. Respir Med 2010;104:188-96.
43. Silkoff PE, Romero FA, Gupta N, Townley RG, Milgrom H. Exhaled nitric oxide in children with asthma receiving Xolair (omalizumab), a monoclonal anti immunoglobulin E antibody. Pediatrics 2004;113:308-12.
44. Zietkowski Z, Skiepko R, Tomasiak-Lozowska MM, Bodzenta-Lukaszyk A. Anti-IgE Therapy with Omalizumab Decreases Endothelin-1 in Exhaled Breath Condensate of Patients with Severe Persistent Allergic Asthma. Respiration doi: 10.1159/000317137. 2011(in press).